Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Targeting type 1 diabetes before and at the clinical onset of disease.

  • L M Bekris
  • T J Kavanagh
  • Åke Lernmark
Publishing year: 2006
Language: English
Pages: 103-124
Publication/Series: Endocrine, Metabolic & Immune Disorders - Drug Targets
Volume: 6
Issue: 1
Document type: Journal article
Publisher: Bentham Science Publishers

Abstract english

Autoimmune type 1 diabetes is strongly associated with a number of immune abnormalities that manifest themselves before and at the time of clinical diagnosis. The clinical onset is associated with a major loss of the pancreatic islet beta cells. Insulin treatment is the only treatment option since numerous trials with agents that suppress or modulate immune function have failed to preserve beta cell function long term. Recent studies suggest that it is possible to predict clinical onset of diabetes by combining genetic with autoantibody testing. In this review we will summarize current and future drug targets for subjects at risk for type 1 diabetes as well as for subjects with recent onset disease. We will also discuss the possible importance of initiating as well as contributing factors such as reactive oxygen species and modified autoantigens. It is speculated that drug targets of factors important to disease pathogenesis may provide safe and effective adductive treatment to preserve beta cell function in autoantibody positive subjects who are at maximum risk for disease.


  • Endocrinology and Diabetes
  • antioxidant
  • Oxidative Stress
  • Viral infections
  • Cadmium
  • CTLA-4
  • variable number tandem repeat (VNTR)


  • Diabetes and Celiac Unit
  • ISSN: 2212-3873
E-mail: ake [dot] lernmark [at] med [dot] lu [dot] se

Principal investigator

Diabetes and Celiac Unit

+46 40 39 19 01

+46 70 616 47 79


Jan Waldenströms gata 35, Malmö


Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00